Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paracetamol regulation findings

This article was originally published in The Tan Sheet

Executive Summary

Researchers found little evidence to support a hypothesis that regulations limiting paracetamol (acetaminophen) package sizes resulted in fewer poisoning deaths. Findings from an observational study by Oliver W. Morgan, Department of Primary Care and Social Medicine, Imperial College, London, et al., published in the April PLOS Medicine contradict a 2004 British Medical Journal study. The BMJ study found U.K. legislation limiting the number of acetaminophen and aspirin tablets sold in retail transactions reduced the number of overdose deaths (1"The Tan Sheet" Nov. 8, 2004, p. 9). Morgan et al. say decreased paracetamol-poisoning mortality coincided with the regulation. However, fatal poisonings involving aspirin and antidepressants also dropped. "This raises the question whether the decline in paracetamol deaths was due to the regulations or was part of a wider trend," they say...

You may also be interested in...

Acetaminophen-Related Overdose Deaths Down In UK Due To Law – BMJ

Legislation in the UK limiting the package sizes for acetaminophen and aspirin has reduced the number of deaths from overdose since its enactment in 1998, a study in the Oct. 29 British Medical Journal says

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts